The first strategy has been attempted in SLE with monoclonal antibodies (mAb), as Sifalimumab and Rontalizumab that block IFNα, without significant results probably due to the absence of inhibition of other IFNs [142,143]. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.